ArticleIranian journal of pharmaceutical research : IJPR
Cancer-Associated Fibroblasts Enhance Oxaliplatin Resistance in Colorectal Cancer Cells via Paracrine IL-6: An In Vitro Study.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mitochondrial Metabolic Reprogramming in Colorectal Cancer-Associated Fibroblasts: An Up-to-Date Review.Cancers · 2026Review
- Unveiling the tumor microenvironment in colorectal cancer therapeutic resistance.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) often develops resistance to oxaliplatin (L-OHP), a key chemotherapeutic agent. Cancer-associated fibroblasts (CAFs) in the tumor microenvironment are implicated in chemoresistance, but their role in L-OHP resistance via interleukin-6 (IL-6) secretion remains unclear. Objectives: The presnt study investigated how CAFs contribute to L-OHP resistance in CRC, focusing on IL-6 secretion and its impact on cancer cell survival. Methods: NIH3T3 fibroblasts were co-cultured with murine (CT26) or human (DLD1) colon cancer cells and treated with L-OHP. The supernatant IL-6 levels were measured by enzyme-linked immunosorbent assay (ELISA). Indirect co-culture using Transwell chambers was employed to separate CAF and tumor cell effects. Conditioned media (CM) from both cell types were collected and analyzed for IL-6. Cytotoxicity assays were conducted to assess the survival of L-OHP-treated CT26 cells in the presence of CAF-derived CM, with or without an IL-6-neutralizing antibody. Results: Co-culture significantly increased IL-6 secretion, which was further amplified by L-OHP. The IL-6 levels in CAF-derived CM were approximately 3.5-fold higher than in tumor cell-derived CM. The CAF-derived CM improved the survival of L-OHP-treated CT26 cells, an effect reversed by IL-6-neutralizing antibodies. Furthermore, adding exogenous IL-6 to tumor cell-derived CM also enhanced survival. Similar IL-6 upregulation in cisplatin-treated CAFs suggests a broader role in platinum-based resistance. Conclusions: The CAFs promote L-OHP resistance in CRC through IL-6 secretion, enhancing cancer cell survival. Therefore, targeting CAFs and IL-6 signaling may help overcome chemoresistance in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.